Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance

Journal of Clinical Epidemiology

Volumn 55, Issue 8, 2002, Pages 833-841

  Schneeweiss, Sebastian ^a   Maclure, Malcolm ^b,c   Soumerai, Stephen B ^d   Walker, Alexander M ^b   Glynn, Robert J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF VICTORIA   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bias; Drug benefit policy; Epidemiological methods; Longitudinal data; Quasi experimental design; Reference pricing

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; QUINAPRIL; RAMIPRIL;

ARTICLE; CANADA; COST BENEFIT ANALYSIS; DRUG COST; DRUG PREFERENCE; HEALTH CARE POLICY; HUMAN; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRIORITY JOURNAL; VALIDATION PROCESS;

ATTITUDE OF HEALTH PERSONNEL; BRITISH COLUMBIA; GUIDELINE ADHERENCE; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LONGITUDINAL STUDIES; PATIENT COMPLIANCE; PRESCRIPTIONS, DRUG; PROGRAM EVALUATION;

EID: 0036697241     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(02)00437-7     Document Type: Article

References (34)

1. Rubin D.B. Estimating causal effects of treatments in randomized and nonrandomized studies. J Educ Psychol. 66:1974;688-701.
2. Cook T.D., Campbell D.T. Quasi-experimentation. Design & analysis issues for field settings. 1979;Houghton Mifflin; Boston.
3. Schneeweiss S., Maclure M., Walker A.M., Grootendorst P., Soumerai S.B. On the evaluation of drug policy changes with longitudinal claims data. The policy maker's versus the clinician's perspective Health Policy. 55:2000;97-109.
4. Urquhart J. Why has patient compliance become important? Clin Res Reg Affairs. 11:1994;81-106.
5. Thomas M., Mann J., Williams S. The impact of reference pricing on clinical lipid control. N Z Med J. 111:1998;292-294.
6. Thomas M., Mann J. Increased thrombotic vascular events after change of statin. Lancet. 352:1998;1830-1831.
7. Weiss N., Heckbert S.R. Thrombotic vascular events after change of statin (letter). Lancet. 353:1999;844.
8. Zelen M. Author's reply to compliance, bias, and power in clinical trials. Biometrics. 47:1991;778-779.
9. Keeler E.B., Malkin J.D., Goldman D.P., Buchanan J.L. Can medical savings accounts for the nonelderly reduce health care costs? JAMA. 275:1996;1666-1671.
10. Sollecito W.A., Gillings D.B. The assessment of health policy changes using the time-reversed crossover design. Health Serv Res. 20:1986;705-736.
11. Pharmacare Antihypertensives. information on reference drug pricing in British Columbia:1997;Pharmacare; Victoria.
12. Office of the Auditor General of British Columbia Managing the cost of drug therapies and fostering appropriate drug use. Section 6. 1998;Office of the Auditor General of British Columbia; Victoria, British Columbia.
13. Angrist J.D., Imbens G.W., Rubin D.B. Identification of causal effects using instrumental variables. JASA. 91:1996;444-455.
14. Bowden R.J., Turkington D.A. Instrumental variables. 1984;Cambridge University Press; Cambridge, UK.
15. Gillings D., Makuc D., Siegel E. Analysis of interrupted time series mortality trends. an example to evaluate regionalized perinatal care Am J Public Health. 71:1981;38-46.
16. Veney J.E., Kaluzny A.D. Evaluation and decision making for health services. 2nd ed:1991;Trend analysis. Ann Arbor, MI: Health Administration Press; Part V.
17. Von Korff M., Wagner E.H., Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 45:1992;197-203.
18. Glynn R.J., Buring J.E. Ways of measuring rates of recurrent events. BMJ. 312:1996;364-367.
19. Liang K.-Y., Zeger S.L. Longitudinal data analysis using generalized linear models. Biometrika. 73:1986;13-22.
20. Kennedy P. A guide to econometrics. 4th ed:1998;MIT Press; Cambridge. p. 123-5.
21. Meyer B.D. Natural and quasi-natural experiments in economics. JBES. 13:1995;151-162.
22. Smith J, Todd P. Does matching overcome Lalonde's critique of nonexperimental estimators? Unpublished manuscript, 2000. http://www.sscl.uwo.ca/economics/faculty/JSmith/Papers.html.
23. Rosenbaum P.R., Rubin D.B. Reducing bias in observational studies using sub-classification on the propensity score. JASA. 79:1984;516-524.
24. Schneeweiss S., Walker A.M., Glynn R.J., Maclure M., Dormuth C., Soumerai S.B. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors. N Engl J Med. 346:2002;822-829.
25. Rosenbaum P., Rubin D.B. The central role of the propensity score in observational studies for causal effects. Biometrika. 70:1983;41-55.
26. Ash A., Shwartz M. Evaluating the performance of risk-adjustment methods. dichotomous outcomes Iezzoni L.I. Risk adjustment for measuring healthcare outcomes. 2nd ed:1997;Health Administration Press; Chicago, IL.
27. Hallas J. Evidence of depression provoked by cardiovascular medication. a prescription sequence symmetry analysis Epidemiology. 7:1996;478-484.
28. Schneeweiss S., Maclure M., Soumerai S.B. Prescription duration after drug copay changes in the elderly. methodological aspects J Am Geriatr Soc. 50:2002;521-525.
29. Schneeweiss S., Soumerai S.B., Glynn R.J., Maclure M., Dormuth C., Walker A.M. Impacts of reference pricing for ACE inhibitors on drug utilization. Can Med Assoc J. 166:2002;737-748.
30. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 79:1989;340-349.
31. Robins J.M. Causal inference from complex longitudinal data. Berkane M. Latent variable modeling and applications to causality. Lecture Notes in Statistics (120). 1997;69-117 Springer Verlag; New York.
32. Robins J.M., Greenland S. Comment on "Identification of causal effects using instrumental variables. JASA. 91:1996;456-458.
33. Robins J.M. Correcting for noncompliance in randomized trials using structural nested mean models. Commun Stat. 23:1994;2379-2412.
34. Schneeweiss S., Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol. 29:2000;891-898.